132 related articles for article (PubMed ID: 28406054)
1. Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia.
Niscola P; Neri B; Catalano G; Morino L; Giovannini M; Scaramucci L; Fratoni S; Noguera NI; Cordone I; de Fabritiis P
Acta Oncol; 2017 Aug; 56(8):1120-1121. PubMed ID: 28406054
[No Abstract] [Full Text] [Related]
2. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
3. Decitabine salvage for
Ferraro F; Gruszczynska A; Ruzinova MB; Miller CA; Percival ME; Uy GL; Pusic I; Jacoby MA; Christopher MJ; Kim MY; Westervelt P; Cashen AF; Schroeder MA; DiPersio JF; Abboud CN; Wartman LD; Gao F; Link DC; Ley TJ; Welch JS
Haematologica; 2022 Jul; 107(7):1709-1713. PubMed ID: 35236053
[No Abstract] [Full Text] [Related]
4. [Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy].
Tauveron-Jalenques U; Lambert J
Bull Cancer; 2024 May; 111(5):435-436. PubMed ID: 38582741
[No Abstract] [Full Text] [Related]
5. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
Stahl M; DeVeaux M; Montesinos P; Itzykson R; Ritchie EK; Sekeres MA; Barnard JD; Podoltsev NA; Brunner AM; Komrokji RS; Bhatt VR; Al-Kali A; Cluzeau T; Santini V; Fathi AT; Roboz GJ; Fenaux P; Litzow MR; Perreault S; Kim TK; Prebet T; Vey N; Verma V; Germing U; Bergua JM; Serrano J; Gore SD; Zeidan AM
Blood Adv; 2018 Apr; 2(8):923-932. PubMed ID: 29685952
[TBL] [Abstract][Full Text] [Related]
6. Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation.
Niscola P; Abruzzese E; Trawinska MM; Palombi M; Tendas A; Giovannini M; Scaramucci L; Cupelli L; Fratoni S; Noguera NI; Catalano G; de Fabritiis P
Acta Oncol; 2017 Oct; 56(10):1331-1333. PubMed ID: 28488914
[No Abstract] [Full Text] [Related]
7. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
[No Abstract] [Full Text] [Related]
8. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
9. Monoclonal Gammopathy Responsive to Decitabine Given for Acute Myeloid Leukemia in a Frail Patient.
Niscola P; Neri B; Morino L; de Fabritiis P
Acta Haematol; 2018; 139(1):58-59. PubMed ID: 29402783
[No Abstract] [Full Text] [Related]
10. Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
Yamamoto R; Yokoyama A; Yoneda M; Ohashi K; Hosoda T; Kagoo T; Boku S; Ueno H; Yano T
Ann Hematol; 2014 Dec; 93(12):2081-2. PubMed ID: 24863693
[No Abstract] [Full Text] [Related]
11. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
12. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
13. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
[TBL] [Abstract][Full Text] [Related]
14. Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.
Yee KW; Brandwein J; Schimmer AD; Gupta V; Del Bel R; Xu W; Minden MD; Schuh AC
Br J Haematol; 2014 Jul; 166(2):303-6. PubMed ID: 24650042
[No Abstract] [Full Text] [Related]
15. Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation.
Zhang B; Pei Z; Wang H; Wu H; Wang J; Bai J; Song Q
Acta Med Okayama; 2022 Feb; 76(1):63-70. PubMed ID: 35237000
[TBL] [Abstract][Full Text] [Related]
16. Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
Villela L; Anders V; Bolaños-Meade J
Anticancer Drugs; 2010 Apr; 21(4):469. PubMed ID: 20216343
[No Abstract] [Full Text] [Related]
17. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
18. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
19. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
